TW201315500A - 用於藥物遞送裝置的卡匣支撐器總成 - Google Patents
用於藥物遞送裝置的卡匣支撐器總成 Download PDFInfo
- Publication number
- TW201315500A TW201315500A TW101121249A TW101121249A TW201315500A TW 201315500 A TW201315500 A TW 201315500A TW 101121249 A TW101121249 A TW 101121249A TW 101121249 A TW101121249 A TW 101121249A TW 201315500 A TW201315500 A TW 201315500A
- Authority
- TW
- Taiwan
- Prior art keywords
- delivery device
- drug delivery
- des
- cassette holder
- proline
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000007246 mechanism Effects 0.000 claims abstract description 11
- 238000003780 insertion Methods 0.000 claims description 34
- 230000037431 insertion Effects 0.000 claims description 34
- 230000013011 mating Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 86
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 84
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 60
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 59
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 55
- 108090001061 Insulin Proteins 0.000 description 41
- 102000004877 Insulin Human genes 0.000 description 41
- 229940125396 insulin Drugs 0.000 description 41
- 230000003248 secreting effect Effects 0.000 description 39
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 35
- 239000004472 Lysine Substances 0.000 description 31
- 229940009098 aspartate Drugs 0.000 description 31
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 22
- 241000790917 Dioxys <bee> Species 0.000 description 21
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 20
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 19
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 19
- 229930182817 methionine Natural products 0.000 description 19
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 15
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 15
- 239000004474 valine Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 9
- 229940122199 Insulin secretagogue Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000712 assembly Effects 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000002473 insulinotropic effect Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 210000002105 tongue Anatomy 0.000 description 3
- MSQCMFLALHZASZ-HVDRVSQOSA-N (2s)-2-aminopentanedioic acid;decan-1-amine Chemical compound OC(=O)[C@@H](N)CCC(O)=O.CCCCCCCCCCN MSQCMFLALHZASZ-HVDRVSQOSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-M aspartate(1-) Chemical compound [O-]C(=O)C([NH3+])CC([O-])=O CKLJMWTZIZZHCS-UHFFFAOYSA-M 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000005489 elastic deformation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229960002913 goserelin Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- ZENKESXKWBIZCV-UHFFFAOYSA-N 2,2,4,4-tetrafluoro-1,3-benzodioxin-6-amine Chemical group O1C(F)(F)OC(F)(F)C2=CC(N)=CC=C21 ZENKESXKWBIZCV-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- -1 oxyl Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2492—Ampoule holder connected to rest of syringe via snap connection
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
本發明係有關於一種用於配送預定劑量之藥劑的藥物遞送裝置,其係包含一殼體。該殼體包含:可容納一驅動機構的一主體(14),可容納具有一活塞之一卡匣的一卡匣支撐器(12),該活塞在該卡匣中配置成可沿著軸向(z)滑動,在該卡匣支撐器(12)與該主體(14)之間的一互連(59),該互連有至少一可位移或可彈性變形閂鎖件(68;74;82)以與一對應支承部(54;90)配對,其中該閂鎖件(68;74;82)在與該主體(14)或該卡匣支撐器(12)之一周向側壁(52,65)實質平行的一方向(z,w)中可位移或可變形。
Description
本發明係有關於藥物遞送裝置的領域,且特別是有關於用以配送預定劑量之液體藥劑的注射裝置,例如筆型注射器。
為本技藝所習知的藥物遞送裝置允許多次調配必要劑量的液體藥劑,例如液體藥物,以及進一步供配送藥劑給患者。此類裝置通常與普通針筒有實質相同的目的。
此類藥物遞送裝置必須符合許多使用者特定要求。例如,在有糖尿病的情形下,許多使用者的身體虛弱而且也有可能視力受損。因此,這些裝置需要強健的結構,而且就部件的操縱與使用者對於操作的了解而言,容易使用。此外,劑量設定必須簡單明確,以及在裝置為用完即棄型而不是可重用型時,該裝置應該製造便宜以及容易處理。為了滿足這些要求,組裝該裝置所需的部件及步驟數目以及製造該裝置之材料種類的總數必須保持最小。
通常待配送的藥劑由卡匣提供,該卡匣係具有與藥物遞送裝置之驅動機構之活塞桿機械互動的可移動活塞或塞子。藉由在遠端方向施加推力至活塞,可由卡匣逐出預定數量的藥用流體。
特別是對於年老或身體虛弱的使用者,裝置在家庭醫療環境中的整體處理必須簡單且高度可靠。如第1圖至第3圖所示,藥物遞送裝置,特別是筆型注射器,通常包含多組件的殼體10。在此,遠端區段通常用作卡匣支撐器12。卡匣支撐器12包含在遠端的帶螺紋承窩16以接受具有帶有對應螺紋之針座(needle hub)20及雙頭注射針(double tipped injection needle)22的針總成18。
卡匣支撐器12更包含在近端區段的插入部份(insert portion)26,藉由它,卡匣支撐器12可至少部份插入藥物遞送裝置之近端殼體組件14(大體以主體14表示)中有對應形狀的遠端插座(receptacle)。主體14用來容納有活塞桿的驅動機構以變成可操作地與卡匣的活塞接合以配置及固定於卡匣支撐器12中。藉由檢驗窗24,可視覺檢驗卡匣的流體或液位(filling level)。
如第1圖至第3圖所示的習知裝置10為用完即棄型。卡匣支撐器12及主體14適合不可釋放地互連。為此目的,卡匣支撐器12的插入部份26包含數個周向分布呈實質矩形的通孔(through opening)28。相應地以及如第3圖所示,主體14的接受用側壁部32包含徑向向內突出椿體(peg)或叉齒(prong)34,其係適合在卡匣支撐器12的插入部份26適當地插入主體14時就可與卡匣支撐器之通孔28配對。
徑向向內突出叉齒34更包含朝向遠端的斜切面36以便輔助叉齒34與通孔28相互接合。此外,卡匣支撐
器12的插入部份26在遠端方向用周向及徑向向外延伸外緣30隔開,在最終組裝組態下,其係抵頂主體14的遠端端面38。
殼體組件12、14通常製造成射出成型的塑膠組件,因為經適當選定的熱塑材料是以具有的彈性為特徵以便支援卡匣支撐器12與主體14的卡扣及導致強制互連。
不過,由於此類藥物遞送裝置10主要想要用在家庭醫療,在故障安全性及強健性方面,特別是考慮到機械碰撞,該裝置必須滿足最高可能標準。
例如,如果裝置10由相當高的地方掉落,機械負載分布可能上升而高於卡匣支撐器12與主體14之互連的關鍵水平。作用於通孔28及/或叉齒34的點應力或點負載可能超過關鍵水平以及卡匣支撐器12與主體14的互連可能中斷,殼體組件12、14鬆開,以及裝置10不再有用。
因此,本發明的目標是要提供一種藥物遞送裝置,其係包含卡匣支撐器與主體的強健、可靠及硬質(mechanically resistant)互連。該互連應可輕易地整合於藥物遞送裝置的現有殼體設計。在生產成本及組裝工作方面,它也應該可輕易地實施。此外,主體與卡匣支撐器的互連應直覺而且容易建立。
本發明係有關於一種用於配送預定劑量之藥劑的藥物遞送裝置。該藥物遞送裝置,通常被設計成筆型注射器,其係包含有至少兩個組件的一殼體,其中位於近端的主體可容納一驅動機構以及位於遠端的卡匣支撐器可容納有配置於其中而可沿著軸向滑動之一活塞的一卡匣。要配置於該主體中的該驅動機構通常有一可位移活塞桿,其係適合可操作地與該卡匣之該活塞接合。以此方式,該活塞桿可施加指向遠端的推力至該活塞用以經由位於遠端的一密封件由該卡匣逐出一預定數量之該藥劑,通常是用注射針刺穿該密封件。
卡匣支撐器與主體將會經由一互連直接互連。該互連最好為強制接合型以及有至少一可位移或可彈性變形閂鎖件,其係適合與一對應支承部(bearing)配對及接合。該閂鎖件在實質平行於主體或卡匣支撐器之周向側壁的一方向(z,w)中可位移或可變形。通常,主體與卡匣支撐器為實質柱形或管形。因此,該至少一閂鎖件適合在卡匣支撐器與主體之間建立一強制互鎖,經由它,卡扣或接合動作只在由主體或卡匣支撐器之周向側壁定義的平面中發生。
該至少一閂鎖件有這種周向位移或變形的好處是主體與卡匣支撐器的相互對應插入部份或插座部份不再必須裝設一通孔於將會與徑向向內或向外延伸叉齒或其類似物接合的周向側壁部份。因此,該至少一閂鎖
件的周向位移或變形支援卡匣支撐器與主體之側壁部份的修改及更加強健的設計。結果,可將該等殼體組件(形成卡匣支撐器與主體的互連)的側壁區段設計成沒有通孔及/或閂鎖件。
再者,可將卡匣支撐器與主體的側壁部份各自設計成為實質封閉的表面,在相當大的機械碰撞下,本質上這可提供提高的機械強度、可靠性及故障安全性。
該互連用多個相互對應與相互配對閂鎖件及支承部建立為較佳,它們與該等殼體組件、卡匣支撐器及主體整合或整體成形為較佳。
在一較佳具體實施例中,卡匣支撐器及/或主體,特別是卡匣支撐器與主體的互連,包含一插入部份與一對應插座部份用於建立卡匣支撐器與主體的一至少部份交錯互連。以此方式,用作插入部份的卡匣支撐器部份可插入該主體的插座部份。然後,在獲得最終組裝組態時,插入部份與插座部份在徑向至少部份重疊。
較佳地,該卡匣支撐器包含在近端區段的插入部份,以及該主體包含在遠端區段的插座部份。以此方式,該卡匣支撐器可至少部份插入該主體以便建立該等殼體組件的強制互連。不過,該藥物遞送裝置的設計不受限於此類組態。一般相信,該卡匣支撐器包含適合接受該主體之插入部份的插座部份。
根據另一具體實施例,該插入部份包含在縱向(z)延伸以及有在周向(w)延伸之至少一可彈性變形伸展件
的至少一閂鎖件。當該閂鎖件該插入部份的遠端縱向延伸時更有利。較佳地,多個閂鎖件設在該插入部份的遠側端面以便攔截或分散機械碰撞至該插入部份的周圍。
在另一較佳方面中,該插座部份包含相對於卡匣支撐器及/或主體之管狀形狀在側向平面(x,y)延伸的至少一支承部。較佳地,該支承部與主體、卡匣支撐器及/或插入部份的縱向範圍及各個閂鎖件實質垂直地延伸為較佳。
該支承部與該主體之插座部份整體成形為較佳以及可進一步在近端方向界定該插座部份。因此,通常由該主體之朝內側壁區段及/或其插座徑向向內延伸的該至少一支承部與該主體本體成形為較佳。經由在該側向平面延伸的該支承部,可將任何在縱向或軸向經由縱向延伸閂鎖件轉移的有向力作用轉移到該支承部以及可進一步傳導及轉移到該主體的形狀封閉型側壁結構。
在另一較佳方面中,該支承部包含至少一軸向通孔以接受該插入部份之該至少一閂鎖件。較佳地,該閂鎖件可彈性變形以便穿經該支承部的通孔。之後,該閂鎖件的周向延伸伸展件可適當地伸展,從而防止該閂鎖件縮回。該閂鎖件也可包含箭頭狀設計,其中各個斜切狀伸展倒鉤實質抑制閂鎖件與支承部的互連鬆開。在處於放鬆組態下,該支承部的通孔因此小於該閂鎖件的周向範圍。該閂鎖件,特別是它的伸展件或倒鉤,必須被彈性擠壓以便穿經該支承部的通孔或插座。
可將該支承部的通孔配置成與該插座部份的周向側壁鄰接。也可配置成與該側壁部份有一徑向距離。
根據另一具體實施例,該支承部以鄰接方式延伸至該插座部份的朝內側壁區段而且更包含一中央通孔以軸向引導該驅動機構的活塞桿。該中央通孔可帶有螺紋以便與該活塞桿的外螺紋合作。替換地,該支承部或腹部(web)的中央通孔也可包含一徑向延伸凹槽或凸出與該活塞桿的凸出或凹槽配對以抑制徑向延伸旋轉。
根據另一具體實施例,該閂鎖件與該對應支承部各自整合於卡匣支撐器與主體之插入部份與插座部份的相互接合側壁區段之至少一縱向延伸肋部(rib)與凹槽。當插入部份與插座部份的側壁區段設有相互對應肋部與凹槽時,可獲得主體與卡匣支撐器的防扭轉互連。
此外,經由在主體與卡匣支撐器之側壁區段中或上的相互對應舌部(tongue)與凹槽,該等殼體組件的相互互連要求在插入部份插入插座部份之前各自與主體與卡匣支撐器旋轉對齊。另外或在上述閂鎖件附近,該凹槽與該對應肋部也可備有相互對應閂鎖件與支承部。例如,該縱向凹槽可包含適合與該肋部之周向延伸閂鎖件配對及接合的周向延伸支承部或個別凹處。
較佳地,該肋部及/或該凹槽對於插入部份與插座部份的相互對應側壁區段是在徑向延伸。特別是,該肋部或有對應形狀之舌部可由該插入部份的側向側壁區段徑向向外突出。因此或替換地,該肋部也可由該插座
部份的朝內側壁區段徑向向內延伸。適合接受該肋部的對應及合作凹槽設於插座或插入部份的對應內或外側壁區段。
在另一較佳方面中,適合與該至少一閂鎖件配對的支承部包含在凹槽中周向延伸的至少一底切(undercutting)。該底切經設計及組態成可與該周向延伸閂鎖件的伸展件或倒鉤合作。
根據另一具體實施例,當插入部份及/或插座部份的側壁區段包含實質封閉表面結構(實質無通孔或結構比較弱的區域)時更有利。以此方式,可結構強化主體與卡匣支撐器之插入部份與插座部份的側壁區段,使得它們對於機械碰撞或衝擊的反應比較不容易破碎。
在另一方面,要建立於卡匣支撐器與主體之間的是不可釋放型互連。因此,一旦建立互連,無法有意也不可能非破壞性地釋放該殼體組件。在消耗卡匣所提供的藥劑時,打算整個拋棄該藥物遞送裝置。
根據另一較佳方面,該藥物遞送裝置備有配置於卡匣支撐器之中的預填充卡匣。該卡匣至少部份填滿可注射藥劑。再者,該藥物遞送裝置更備有配置於該主體之中的一驅動機構,其係備妥施加指向遠端的推力至該卡匣的活塞,其目的是正確地逐出預定劑量或數量的藥劑。
如本文所使用的,術語“藥劑”係指包含至少一醫學上活性化合物的藥劑配方,
其中,在一具體實施例中,該醫學上活性化合物有達1500 Da的分子量及/或為縮氨酸(peptide)、蛋白質、多醣(polysaccharide)、疫苗、DNA、RNA、酶、抗體、荷爾蒙或寡核苷酸(oligonucleotide)、或上述醫學上活性化合物的混合物,其中,在另一具體實施例中,該醫學上活性化合物適於治療及/或預防糖尿病或與糖尿病有關的併發症,例如糖尿病性視網膜病變(diabetic retinopathy),血栓栓塞症(thromboembolism disorders),例如深靜脈或肺血栓栓塞(pulmonary thromboembolism)、急性冠狀動脈綜合症(acute coronary syndrome,ACS)、心絞痛(angina)、心肌梗塞(myocardial infarction)、癌症、黃斑部病變(macular degeneration)、發炎,花粉過敏,動脈粥樣硬化(atherosclerosis)及/或類風濕關節炎(rheumatoid arthritis),其中,在另一具體實施例中,該醫學上活性化合物包含用於治療及/或預防糖尿病或與糖尿病有關之併發症(例如,糖尿病性視網膜病變)的至少一縮氨酸,其中,在又一具體實施例中,該醫學上活性化合物包含至少一人類胰島素(human insulin)或人類胰島素類似物或衍生物,胰高血糖素樣縮氨酸(glucagon-like peptide,GLP-1)或彼等之類似物或衍生物,或促胰島素分泌肽-3(exedin-3)或促胰島素分泌肽(exedin-4)或促胰島素分泌肽-3或促胰島素分泌肽-4的類似物或衍生物。
胰島素類似物的例子有:Gly(A21)、Arg(B31)、Arg(B32)人類胰島素;Lys(B3)、Glu(B29)人類胰島素;Lys(B28)、Pro(B29)人類胰島素;Asp(B28)人類胰島素;人類胰島素,其中用Asp、Lys、Leu、Val或Ala取代在B28位的脯胺酸(proline),以及其中可用Pro取代在B29位的Lys;Ala(B26)人類胰島素;Des(B28-B30)人類胰島素;Des(B27)人類胰島素;以及Des(B30)人類胰島素。
胰島素衍生物的例子有:B29-N-肉豆蔻醯基-des(B30)人類胰島素;B29-N-棕櫚醯基-des(B30)人類胰島素;B29-N-肉豆蔻醯基人類胰島素;B29-N-棕櫚醯基人類胰島素;B28-N-肉豆蔻醯基LysB28ProB29人類胰島素;B28-N-棕櫚醯基-LysB28ProB29人類胰島素;B30-N-肉豆蔻醯基-ThrB29LysB30人類胰島素;B30-N-棕櫚醯基-ThrB29LysB30人類胰島素;B29-N-(N-棕櫚醯基-Y-麩胺醯基)-des(B30)人類胰島素;B29-N-(N-石膽基-Y-麩胺醯基)-des(B30)人類胰島素;B29-N-((ω-羧基十七醯基)-des(B30)人類胰島素;以及B29-N-(ω-羧基十七醯基)人類胰島素。
促胰島素分泌肽-4(Exedin-4)例如意指促胰島素分泌肽-4(1-39)、有如下順序的縮氨酸:氫基-組胺酸-甘胺酸-穀胺酸-甘胺酸-酪胺酸-苯丙胺酸-酪胺酸-絲胺酸-天冬胺酸-亮胺酸-絲胺酸-賴胺酸-穀胺醯胺-蛋胺酸-穀胺酸-穀胺酸-穀胺酸-丙胺酸-纈胺酸-精胺酸-亮胺酸-苯丙
胺酸-異白胺酸-穀胺酸-色胺酸-亮胺酸-賴胺酸-天冬胺醯胺-甘胺酸-甘胺酸-脯胺酸-絲胺酸-絲胺酸-甘胺酸-丙胺酸-脯胺酸-脯胺酸-脯胺酸-絲胺酸-胺基(H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2)。
促胰島素分泌肽-4衍生物為例如由下列清單選出的化合物:氫基-(賴胺酸)4-des脯胺酸36,des脯胺酸37促胰島素分泌肽-4(1-39)-胺基(H-(Lys)4-des Pro36,des Pro37 Exedin-4(1-39)-NH2)、氫基-(賴胺酸)5-des脯胺酸36,des脯胺酸37促胰島素分泌肽-4(1-39)-胺基(H-(Lys)5-des Pro36,des Pro37 Exedin-4(1-39)-NH2)、des脯胺酸36[天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Asp28]Exedin-4(1-39))、des脯胺酸36[異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[IsoAsp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14,Asp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14,IsoAsp28]
Exedin-4(1-39))、des脯胺酸36[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Trp(O2)25,Asp28]Exedin-4(1-39))、des脯胺酸36[色胺酸(二氧基)25,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Trp(O2)25,IsoAsp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14 Trp(O2)25,Asp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14色胺酸(二氧基)25,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14 Trp(O2)25,IsoAsp28]Exedin-4(1-39));或des脯胺酸36[天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Asp28]Exedin-4(1-39))、des脯胺酸36[異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[IsoAsp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14,Asp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14,IsoAsp28]Exedin-4(1-39))、
des脯胺酸36[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Trp(O2)25,Asp28]Exedin-4(1-39))、des脯胺酸36[色胺酸(二氧基)25,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Trp(O2)25,IsoAsp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14 Trp(O2)25,Asp28]Exedin-4(1-39))、des脯胺酸36[蛋胺酸(氧基)14色胺酸(二氧基)25,異天冬胺酸28]促胰島素分泌肽-4(1-39)(des Pro36[Met(O)14 Trp(O2)25,IsoAsp28]Exedin-4(1-39)),其中-賴胺酸6-胺基(-Lys6-NH2)群可鍵結至促胰島素分泌肽-4衍生物的C端;或有下列順序的促胰島素分泌肽-4衍生物:分泌肽-4(1-39)-賴胺酸6-胺基(H-(Lys)6-des Pro36[Asp28]Exedin-4(1-39)-Lys6-NH2)、des天冬胺酸28脯胺酸36,脯胺酸37,脯胺酸38促胰島素分泌肽-4(1-39)-胺基(des Asp28 Pro36,Pro37,Pro38Exedin-4(1-39)-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸38[天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-(Lys)6-des Pro36,Pro38[Asp28]Exedin-4(1-39)-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸
37,脯胺酸38[天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-Asn-(Glu)5des Pro36,Pro37,Pro38[Asp28]Exedin-4(1-39)-NH2)、des脯胺酸36,脯胺酸37,脯胺酸38[天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(des Pro36,Pro37,Pro38[Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-賴胺酸6-胺基(H-(Lys)6-des Pro36[Trp(O2)25,Asp28]Exedin-4(1-39)-Lys6-NH2)、氫基-des天冬胺酸28脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25]促胰島素分泌肽-4(1-39)-胺基(H-des Asp28 Pro36,Pro37,Pro38[Trp(O2)25]Exedin-4(1-39)-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽
-4(1-39)-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exedin-4(1-39)-NH2)、氫基-天冬胺酸-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exedin-4(1-39)-NH2)、des脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-天冬胺酸-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-賴胺酸6-胺基(H-(Lys)6-des Pro36[Met(O)14,Asp28]Exedin-4(1-39)-Lys6-NH2)、des蛋胺酸(氧基)14天冬胺酸28脯胺酸36,脯胺酸
37,脯胺酸38促胰島素分泌肽-4(1-39)-胺基(des Met(O)14 Asp28 Pro36,Pro37,Pro38 Exedin-4(1-39)-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-(Lys)6-desPro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-NH2)、des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(des Pro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-Asn-(Glu)5 des Pro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、
氫基-賴胺酸6-des脯胺酸36[蛋胺酸(氧基)14,色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-賴胺酸6-胺基(H-Lys6-des Pro36[Met(O)14,Trp(O2)25,Asp28]Exedin-4(1-39)-Lys6-NH2)、氫基-des天冬胺酸28脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,色胺酸(二氧基)25]促胰島素分泌肽-4(1-39)-胺基(H-des Asp28 Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25]Exedin-4(1-39)-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Met(O)14,Asp28]Exedin-4(1-39)-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]Exedin-4(1-39)-NH2)、des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(des Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]Exedin-4(1-39)-(Lys)6-NH2)、氫基-(賴胺酸)6-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,色胺酸(二氧基)25,天冬胺酸28]促
胰島素分泌肽-4(S1-39)-(賴胺酸)6-胺基(H-(Lys)6-des Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]Exedin-4(S1-39)-(Lys)6-NH2)、氫基-天冬胺醯胺-(穀胺酸)5-des脯胺酸36,脯胺酸37,脯胺酸38[蛋胺酸(氧基)14,色胺酸(二氧基)25,天冬胺酸28]促胰島素分泌肽-4(1-39)-(賴胺酸)6-胺基(H-Asn-(Glu)5-des Pro36,Pro37,Pro38[Met(O)14,Trp(O2)25,Asp28]Exedin-4(1-39)-(Lys)6-NH2);或前述促胰島素分泌肽-4衍生物中之任一的醫藥上可接受鹽或溶劑合物(solvate)。
荷爾蒙的例子有:垂體荷爾蒙或下丘腦荷爾蒙或調節性活性縮氨酸以及如列於Rote Liste(2008版)第50章的拮抗物,例如促性腺激素(Gonadotropine)(促濾泡素(Follitropin)、促黃體素(Lutropin)、絨毛膜性腺激素(Choriongonadotropin)、促月經素(Menotropin)),生長激素(Somatropine,Somatropin),去氨加壓素(Desmopressin),特利加壓素(Terlipressin),人工促性腺素戈那瑞林(Gonadorelin),人工促性腺素曲普瑞林(Triptorelin),人工促性線素亮丙瑞林(Leuprorelin),噴鼻劑布舍瑞林(B使用者elin),促性腺素拮抗劑那法瑞林(Nafarelin),人工促黃體素戈舍瑞林(Goserelin)。
多醣的例子為糖胺聚糖(glucosaminoglycane),例如玻尿酸(hyaluronic acid)、肝素(heparin)、低分子量肝素或超低分子量肝素或其衍生物,或上述多醣的硫酸化型
(例如,聚硫酸化型),及/或其醫藥上可接受鹽。聚硫酸化低分子量肝素的醫藥上可接受鹽例如為依諾肝素鈉(enoxaparin sodium)。
醫藥上可接受之鹽類的例子為酸加成鹽以及鹼鹽。酸加成鹽的例子為氫氯酸鹽或氫溴酸鹽。鹼鹽類的例子為含有一陽離子的鹽類,其中之陽離子係從以下之鹼金族或鹼土族離子中選出,例如鈉離子或鉀離子或鈣離子,或銨離子N+(R1)(R2)(R3)(R4),其中之R1到R4係各自獨立,意指:氫、視需要經取代之C1-C6烷基、視需要經取代之C2-C6烯基、視需要經取代之C6-C10芳基、或視需要經取代之C6-C10雜芳基。醫藥上可接受的其他鹽類範例可參見第十七版的‘‘Remington’s Pharmaceutical Sciences”(1985)(作者:Alfonso R。Gennaro,出版社:美國賓州之Mark Publishing Company,Easton),以及藥理學百科大全(Encyclopedia of Pharmaceutical Technology)。醫藥上可接受之溶劑合物的例子為水合物。
熟諳此藝者會明白本發明可做出各種修改及變體而不脫離本發明的精神及範疇。此外,應注意使用於申請專利範圍的任何元件符號不應被視為是要限制本發明的範疇。
第4圖圖示主體殼體組件50的插座部份51,其係
適合接受卡匣支撐器60中有對應形狀的插入部份66。與如第1圖至第3圖所示的具體實施例對比,主體50與卡匣支撐器60的側壁區段52、65穿包含無徑向通孔的完全封閉表面結構。
藉由如第4圖所示之具體實施例可得到的閂鎖機構59係基於由插入部份66近端沿著縱向(z)延伸的箭頭狀閂鎖件68。主體50包含有支承部54在側向平面(x,y)中延伸的管狀或柱形側壁52。也用作側向腹部的支承部54與主體50的側向側壁52整體成形以及包含適合接受插入部份66之縱向延伸閂鎖件68及與其配對的至少一軸向通孔58。
如第4圖所示的閂鎖件68包含兩個對立及周向延伸的伸展件或倒鉤70,它們在通過支承部54之通孔58被推進時可擠壓或周向變形。用在周向延伸伸展件70之間延伸的縱向狹縫72可支援倒鉤70的回彈或彈性變形。
閂鎖件68的定位及周向分布與支承部54之軸向通孔58的周向大小及位置對應。如第4圖所示的支承部54也包含居中及帶有螺紋的通孔56,其係用來軸向引導不再圖示於此之驅動機構的活塞桿。
如第4圖所示的閂鎖件68在縱向(z)及周向(w)延伸。彼等係特別適合在周向(w)可回彈或彈性變形以便與支承部54建立強制互鎖。以此方式,基於強制卡扣解決方案可獲得主體50與卡匣支撐器60的相互互連而
不需要在插座部份51與插入部份66的側壁區段52、65中裝設通孔或其他使結構變弱的部份。
通常,插入部份66的縱向延伸部份與插座部份51的縱向延伸部份實質匹配。在獲得藥物遞送裝置的最終組裝組態時,卡匣支撐器60與主體50在徑向及縱向(z)都抵緊。其目的在於,主體50的遠側及下端面在縱向抵緊卡匣支撐器60的徑向延伸周向外緣64。相應地,插入部份66的近側端面在最終組裝組態下可抵緊橫向或側向延伸支承部54。周向外緣64進一步使卡匣支撐器12的遠側及實質管狀形狀部份62與插入部份66分離。
第5圖圖示閂鎖件74的替代具體實施例,其係包含有點像箭頭的形成及在長形承窩部份76的自由端有兩個斜切倒鉤78。倒鉤78意圖在於與支承部54的近側表面配對及抵緊,如第4圖所示。
第6圖及第7圖的具體實施例圖示另一卡扣組態。在此,卡匣支撐器60的插入部份66包含有周向延伸閂鎖件82的實質縱向延伸肋部或舌部80,該等周向延伸閂鎖件82包含與縱向凹槽86中有對應形狀之凹處88配對的周向延伸倒鉤84,該縱向凹槽86係設於主體組件50之插座51的朝內側壁區段52。
在此,當周向突出倒鉤或伸展件84包含允許通過凹槽86在縱向(z)推進閂鎖件82直到到達如第7圖所示的最終組裝組態的足夠彈性時更有利。適合容納放鬆閂
鎖件82的凹處88包含實質在側向平面(z,w)中延伸的底切90。不過,也可想到其他的具體實施例,其中底切90與周向突出倒鉤包含延伸方向與組裝方向(z)之角度實質小於90度的相互對應抵頂面。
第6圖及第7圖的具體實施例可與第4圖的具體實施例任意組合,因此可能提供藥物遞送裝置(例如,筆型)之卡匣支撐器60與主體50的附加固定。
10‧‧‧藥物遞送裝置
12‧‧‧卡匣支撐器
14‧‧‧主體
16‧‧‧帶螺紋承窩
18‧‧‧針總成
20‧‧‧針座承窩
22‧‧‧注射針
24‧‧‧檢驗窗
26‧‧‧插入部份
28‧‧‧通孔
30‧‧‧外緣
32‧‧‧插座
34‧‧‧叉齒
36‧‧‧斜切面
38‧‧‧端面
50‧‧‧主體
51‧‧‧插座部份
52‧‧‧側壁
54‧‧‧支承部
56‧‧‧通孔
58‧‧‧通孔
59‧‧‧互連
60‧‧‧卡匣支撐器
62‧‧‧遠端部份
64‧‧‧外緣
65‧‧‧側壁
66‧‧‧插入部份
68‧‧‧閂鎖件
70‧‧‧倒鉤
72‧‧‧狹縫
74‧‧‧閂鎖件
76‧‧‧承窩
78‧‧‧倒鉤
80‧‧‧肋部
82‧‧‧閂鎖件
84‧‧‧倒鉤
86‧‧‧凹槽
88‧‧‧插座
90‧‧‧底切
以下參考附圖來描述本發明的較佳具體實施例。
第1圖的展開圖示意圖示根據先前技術的藥物遞送裝置,
第2圖單獨圖示第1圖的卡匣支撐器,以及
第3圖示意圖示穿過第1圖之主體組件的橫截面,
第4圖根據第一具體實施例圖示主體與卡匣支撐器的互連,
第5圖示意圖示閂鎖件的替代設計,
第6圖示意圖示整合於卡匣支撐器之縱向肋部的閂鎖件,以及
第7圖示意圖示經由第6圖之閂鎖件可得到的強制互鎖。
w‧‧‧周向
50‧‧‧主體
51‧‧‧插座部份
52‧‧‧側壁
54‧‧‧支承部
56‧‧‧通孔
58‧‧‧通孔
59‧‧‧互連
60‧‧‧卡匣支撐器
62‧‧‧遠端部份
64‧‧‧外緣
65‧‧‧側壁
66‧‧‧插入部份
68‧‧‧閂鎖件
70‧‧‧倒鉤
72‧‧‧狹縫
Claims (13)
- 一種用於配送預定劑量之藥劑的藥物遞送裝置,其係包含一殼體,該殼體具有:一主體(14)可容納一驅動機構,一卡匣支撐器(12)可容納具有一活塞之一卡匣,該活塞在該卡匣中配置成可沿著軸向(z)滑動,一互連(59)在該卡匣支撐器(12)與該主體(14)之間,該互連有至少一可位移或可彈性變形閂鎖件(68;74;82)以與一對應支承部(54;90)配對,其中該閂鎖件(68;74;82)在與該主體(14)或該卡匣支撐器(12)之一周向側壁(52,65)實質平行的一方向(z,w)中可位移或可變形。
- 如申請專利範圍第1項之藥物遞送裝置,其中該卡匣支撐器(12)與該主體(14)包含一插入部份(66)與一對應插座部份(51)用於建立該卡匣支撐器(12)與該主體(14)的一至少部份交錯互連。
- 如申請專利範圍第2項之藥物遞送裝置,其中該卡匣支撐器(12)包含可插入該主體(14)之該插座部份(51)的該插入部份(66),或反之亦然。
- 如申請專利範圍第2項或第3項之藥物遞送裝置,其中該插入部份(66)包含該至少一閂鎖件(68;74;82)在縱向(z)延伸以及有在周向(w)延伸之至少一可彈性變形伸展件(70;78;84)。
- 如申請專利範圍第2項至第4項之任一項之藥物 遞送裝置,其中該插座部份(51)包含該至少一支承部(54;90)對於該卡匣支撐器(12)及/或該主體(14)之一管狀形狀在一側向平面(x,y)中延伸。
- 如申請專利範圍第5項之藥物遞送裝置,其中該支承部(54)包含至少一軸向通孔(58)可接受該閂鎖件(68;74;82)。
- 如申請專利範圍第5項或第6項之藥物遞送裝置,其中該支承部(54)以鄰接方式延伸至該插座部份(51)的一朝內側壁區段(52)以及包含一中央通孔(56)以軸向引導該驅動機構的一活塞桿。
- 如申請專利範圍第2項至第7項中之任一項的藥物遞送裝置,其中該閂鎖件(82)與該對應支承部(90)各自整合於該卡匣支撐器(12)與該主體(14)之該插入部份(66)與該插座部份(51)的相互接合側壁區段(52,65)之至少一縱向延伸肋部(80)或凹槽(86)。
- 如申請專利範圍第8項之藥物遞送裝置,其中該舌部(80)及/或彼之閂鎖件(82)由該插入部份(66)之一側向側壁區段(65)徑向向外突出。
- 如申請專利範圍第8項或第9項之藥物遞送裝置,其中該支承部(90)包含至少一底切(90),該至少一底切(90)在該凹槽(86)中周向延伸以及適合與在周向(w)延伸之該閂鎖件(82)的一伸展件(84)配對。
- 如申請專利範圍第2項至第10項中之任一項的藥 物遞送裝置,其中該插入部份(66)及/或該插座部份(51)的側壁區段(52,65)包含無通孔的一封閉表面結構。
- 如以上所有申請專利範圍中之任一項的藥物遞送裝置,其中該互連(59)為不可釋放型。
- 如以上所有申請專利範圍中之任一項的藥物遞送裝置,其更包含填充一藥劑的一卡匣,該卡匣係配置於該卡匣支撐器(12)中。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11170308 | 2011-06-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201315500A true TW201315500A (zh) | 2013-04-16 |
| TWI574708B TWI574708B (zh) | 2017-03-21 |
Family
ID=44454112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101121249A TWI574708B (zh) | 2011-06-17 | 2012-06-14 | 用於藥物遞送裝置的卡匣支撐器總成 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9731075B2 (zh) |
| EP (1) | EP2720738B1 (zh) |
| JP (1) | JP6057991B2 (zh) |
| KR (1) | KR20140050010A (zh) |
| CN (1) | CN103732278B (zh) |
| AR (1) | AR086930A1 (zh) |
| AU (1) | AU2012269060B2 (zh) |
| BR (1) | BR112013032089A2 (zh) |
| CA (1) | CA2838786A1 (zh) |
| DK (1) | DK2720738T3 (zh) |
| IL (1) | IL229850A (zh) |
| MX (1) | MX357609B (zh) |
| RU (1) | RU2603289C2 (zh) |
| TW (1) | TWI574708B (zh) |
| WO (1) | WO2012171981A1 (zh) |
| ZA (1) | ZA201309240B (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2414400B (en) | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
| GB2414402B (en) | 2004-05-28 | 2009-04-22 | Cilag Ag Int | Injection device |
| GB2414775B (en) | 2004-05-28 | 2008-05-21 | Cilag Ag Int | Releasable coupling and injection device |
| GB2425062B (en) | 2005-04-06 | 2010-07-21 | Cilag Ag Int | Injection device |
| GB2424836B (en) | 2005-04-06 | 2010-09-22 | Cilag Ag Int | Injection device (bayonet cap removal) |
| US20110098656A1 (en) | 2005-09-27 | 2011-04-28 | Burnell Rosie L | Auto-injection device with needle protecting cap having outer and inner sleeves |
| GB2438591B (en) | 2006-06-01 | 2011-07-13 | Cilag Gmbh Int | Injection device |
| GB2461085B (en) | 2008-06-19 | 2012-08-29 | Cilag Gmbh Int | Injection device |
| GB2515038A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Injection device |
| GB2515039B (en) | 2013-06-11 | 2015-05-27 | Cilag Gmbh Int | Injection Device |
| GB2515032A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Guide for an injection device |
| GB2517896B (en) | 2013-06-11 | 2015-07-08 | Cilag Gmbh Int | Injection device |
| KR102546986B1 (ko) | 2015-03-23 | 2023-06-26 | 사노피-아벤티스 도이칠란트 게엠베하 | 주사 장치를 위한 하우징 및 하우징 구성요소들의 상호연결 |
| EP3241581A1 (en) * | 2016-05-03 | 2017-11-08 | Sanofi-Aventis Deutschland GmbH | Non-releasable snap connection of cartridge holder to syringe |
| EP3664866B1 (en) | 2017-08-10 | 2022-01-05 | West Pharma. Services Il, Ltd. | Injector cartridge door locking mechanism |
| US11679207B2 (en) * | 2018-02-13 | 2023-06-20 | Union Medico Aps | Injection device and adaptor |
| EP3808393A1 (en) * | 2019-10-15 | 2021-04-21 | Ypsomed AG | Cartridge fixation for a drug delivery device |
| MX2022007606A (es) * | 2019-12-18 | 2022-07-19 | Sanofi Sa | Conjunto de cartucho para un dispositivo de administracion de farmacos y dispositivo de administracion de farmacos. |
| EP3912661A1 (en) * | 2020-05-20 | 2021-11-24 | Becton Dickinson France | Autoinjector housing |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3790048A (en) * | 1972-07-28 | 1974-02-05 | Ortho Pharma Corp | Incremental dose dispenser |
| BR7806153A (pt) * | 1978-09-19 | 1980-04-01 | Halen Elliot Brasil Ind Com Eq | Injetor hipodermico a pressao para vacinacao intermitente |
| US4425120A (en) * | 1982-04-15 | 1984-01-10 | Sampson Norma A | Shielded hypodermic syringe |
| EP0109913A3 (fr) * | 1982-11-03 | 1984-09-12 | Micro-Mega | Seringue dentaire pour injections intra-ligamentaires |
| US4710178A (en) * | 1982-11-03 | 1987-12-01 | Micro-Mega S.A. | Precision injection system and method for intraligmental anesthesia |
| US4731059A (en) * | 1986-10-14 | 1988-03-15 | Medical Safety Products, Inc. | Combination needle shield/needle guard device positively locked onto detachable needle assemblies for an evacuated blood collection system and a hypodermic syringe |
| US4886495A (en) * | 1987-07-08 | 1989-12-12 | Duoject Medical Systems Inc. | Vial-based prefilled syringe system for one or two component medicaments |
| US5569190A (en) * | 1987-06-08 | 1996-10-29 | D'antonio; Nicholas F. | Hypodermic fluid dispenser |
| GB8713810D0 (en) * | 1987-06-12 | 1987-07-15 | Hypoguard Uk Ltd | Measured dose dispensing device |
| CH675078A5 (zh) * | 1988-01-22 | 1990-08-31 | Nosta Ag | |
| US4973318A (en) * | 1988-02-10 | 1990-11-27 | D.C.P. Af 1988 A/S | Disposable syringe |
| US4923446A (en) * | 1988-04-14 | 1990-05-08 | Page Mary J | Shield for devices capable of penetrating skin |
| US4917673A (en) * | 1988-10-31 | 1990-04-17 | Coplin Allan J | Assembly for the protection against inadvertent puncture by medical needles |
| US4900311A (en) * | 1988-12-06 | 1990-02-13 | Lawrence Stern | Hypodermic syringe |
| US4966592A (en) * | 1989-05-05 | 1990-10-30 | Burns Cameron A | Protective sleeve for hypodermic needle |
| US5279586A (en) * | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Reusable medication delivery pen |
| MY115132A (en) * | 1992-05-19 | 2003-04-30 | Pharmaplan Gmbh | Injection device for single use |
| GB9212742D0 (en) * | 1992-06-16 | 1992-07-29 | Sterimatic Holdings Ltd | Syringe or blood collection system |
| US5545147A (en) * | 1992-10-20 | 1996-08-13 | Eli Lilly And Company | Anti-backup improvement for hypodermic syringes |
| US5346480A (en) * | 1992-12-14 | 1994-09-13 | Q-Med, Inc. | Syringe with retractable needle |
| GB9310163D0 (en) * | 1993-05-18 | 1993-06-30 | Owen Mumford Ltd | Improvements relating to injection devices |
| AUPM922394A0 (en) * | 1994-11-03 | 1994-11-24 | Astra Pharmaceuticals Pty Ltd | Plastic syringe with overcap |
| US5595566A (en) * | 1995-01-31 | 1997-01-21 | Unique Management Enterprises, Inc. | Apparatus for shielding a syringe needle |
| WO1996027400A1 (en) * | 1995-03-07 | 1996-09-12 | Eli Lilly And Company | Recyclable medication dispensing device |
| US5591138A (en) * | 1995-08-10 | 1997-01-07 | Vaillancourt; Vincent L. | Protected needle assembly |
| US5674204A (en) * | 1995-09-19 | 1997-10-07 | Becton Dickinson And Company | Medication delivery pen cap actuated dose delivery clutch |
| US5688241A (en) * | 1996-04-15 | 1997-11-18 | Asbaghi; Hooman Ali | Automatic non-reusable needle guard |
| US5713857A (en) * | 1996-06-28 | 1998-02-03 | Becton Dickinson France, S.A. | Sequential stopper |
| US5851197A (en) * | 1997-02-05 | 1998-12-22 | Minimed Inc. | Injector for a subcutaneous infusion set |
| US6391414B1 (en) * | 1997-03-07 | 2002-05-21 | Pharmacia Ab | Structure and method for joining parts |
| US5957896A (en) * | 1997-08-11 | 1999-09-28 | Becton, Dickinson And Company | Medication delivery pen |
| US5931817A (en) * | 1997-09-12 | 1999-08-03 | Becton Dickinson And Company | Pen needle assembly |
| SE9901736D0 (sv) * | 1999-05-12 | 1999-05-12 | Pharmacia & Upjohn Ab | Injectino device and method for ITS operation |
| US20010031949A1 (en) * | 1999-06-18 | 2001-10-18 | Asbaghi Hooman A. | Protective device for a prefilled injection syringe |
| US20020004652A1 (en) * | 1999-06-18 | 2002-01-10 | Asbaghi Hooman A. | Protective device for a fillable injection syringe |
| GB0007071D0 (en) * | 2000-03-24 | 2000-05-17 | Sams Bernard | One-way clutch mechanisms and injector devices |
| US6663602B2 (en) * | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
| EP3138598B1 (en) * | 2000-08-02 | 2019-10-23 | Becton, Dickinson and Company | Pen needle and safety shield system |
| GB0021887D0 (en) * | 2000-09-06 | 2000-10-18 | Provalis Diagnostics Ltd | Assay device |
| GB0107608D0 (en) * | 2001-03-27 | 2001-05-16 | Dca Design Int Ltd | Improvements in and relating to an injection device |
| GB0107601D0 (en) * | 2001-03-27 | 2001-05-16 | Dca Design Int Ltd | Improvements in and relating to and injection device |
| DK2258424T3 (da) * | 2001-05-16 | 2013-02-18 | Lilly Co Eli | Indretning til injektion af lægemidler |
| PT1448256E (pt) * | 2001-11-30 | 2006-06-30 | Novo Nordisk As | Montagem de uma agulha de seguranca |
| US20030105430A1 (en) * | 2001-11-30 | 2003-06-05 | Elan Pharma International Limited Wil House | Automatic injector |
| US20030144630A1 (en) * | 2002-01-28 | 2003-07-31 | Chang Yu Kang | Safety syringe |
| ATE337810T1 (de) * | 2002-10-01 | 2006-09-15 | Becton Dickinson Co | Stiftförmige medikamentenspritze |
| US6884237B2 (en) * | 2002-12-10 | 2005-04-26 | Inviro Medical Devices, Inc. | Position guide for a needle guard |
| US7740597B2 (en) * | 2002-12-11 | 2010-06-22 | Ethicon Endo-Surgery, Inc. | Biopsy device with sample tube |
| GB0304824D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| EP2210634A1 (en) * | 2009-01-22 | 2010-07-28 | Sanofi-Aventis Deutschland GmbH | Drug delivery device dose setting mechanism |
| GB0306642D0 (en) * | 2003-03-22 | 2003-04-30 | Dca Design Int Ltd | Improvements in and relating to an injector for a medical product |
| PT1656170T (pt) * | 2003-08-12 | 2019-05-31 | Lilly Co Eli | Aparelho para dispensar medicação com parafusos com rosca tripla para vantagem mecânica |
| EP1732628B1 (en) * | 2004-03-30 | 2011-09-28 | Eli Lilly & Company | Medication dispensing apparatus with gear set having drive member accommodating opening |
| US20060069354A1 (en) * | 2004-09-30 | 2006-03-30 | Buenger David R | Syringe activation device |
| US7597685B2 (en) * | 2004-11-24 | 2009-10-06 | Shl Group Ab | Injection device |
| US7297136B2 (en) * | 2004-12-06 | 2007-11-20 | Wyrick Ronald E | Medicine injection devices and methods |
| JP4903160B2 (ja) * | 2005-01-18 | 2012-03-28 | ウォックハート アメリカズ インコーポレイテッド | ペン型薬物注入デバイス |
| EP1683537A1 (en) | 2005-01-25 | 2006-07-26 | Pfizer Health AB | Injection device for administering a medication liquid |
| US8062252B2 (en) * | 2005-02-18 | 2011-11-22 | Becton, Dickinson And Company | Safety shield system for a syringe |
| FR2884723B1 (fr) * | 2005-04-20 | 2008-03-14 | Becton Dickinson France Soc Pa | Dispositif de protection d'un dispositif d'injection |
| GB0600212D0 (en) * | 2006-01-06 | 2006-02-15 | Liversidge Barry P | Medical needle safety device |
| CN101500630B (zh) * | 2006-07-03 | 2012-05-30 | 诺沃-诺迪斯克有限公司 | 用于注射装置的联结器 |
| GB2443390A (en) * | 2006-11-03 | 2008-05-07 | Owen Mumford Ltd | Medicine delivery apparatus |
| EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| EP1923083A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Drive mechanisms for use in drug delivery devices |
| EP1923084A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| WO2009040602A1 (en) * | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
| US8771237B2 (en) * | 2007-12-20 | 2014-07-08 | Novo Nordisk A/S | Injection device for delivering a fixed dose of liquid drug |
| US10124117B2 (en) * | 2008-05-05 | 2018-11-13 | Becton, Dickinson And Company | Drug delivery device having cartridge with enlarged distal end |
| EP2123317A1 (en) * | 2008-05-20 | 2009-11-25 | Sanofi-Aventis Deutschland GmbH | Drive assembly suitable for use in drug delivery device and drug delivery device |
| DE102008048988A1 (de) * | 2008-09-25 | 2010-04-08 | Fresenius Kabi Deutschland Gmbh | Vorrichtung zum Anschluss einer Spritze an ein Behältnis oder eine Schlauchleitung |
| US8475414B2 (en) * | 2008-12-02 | 2013-07-02 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device and method for operating a medication delivery device |
| EP2201972A1 (en) * | 2008-12-23 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Fixed dose injection device with resettable drive mechanism |
| EP2201974A1 (en) * | 2008-12-23 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Medication delivery device |
| EP2201970A1 (en) * | 2008-12-23 | 2010-06-30 | Sanofi-Aventis Deutschland GmbH | Drug delivery device |
| EP2208503A1 (en) * | 2009-01-20 | 2010-07-21 | Sanofi-Aventis Deutschland GmbH | Drive assembly and medication delivery device |
| CN102612381B (zh) * | 2009-03-20 | 2015-09-09 | 安塔瑞斯制药公司 | 危险试剂注入系统 |
| DK2424599T3 (da) * | 2009-04-27 | 2020-08-24 | Shl Medical Ag | Sikkerhedspenkanyleindretning |
| US9125994B2 (en) * | 2009-06-01 | 2015-09-08 | Sanofi—Aventis Deutschland GmbH | Drug delivery device with dose dial sleeve rotational stop |
| US8257319B2 (en) * | 2009-06-01 | 2012-09-04 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device inner housing having helical spline |
| US8728043B2 (en) * | 2009-06-01 | 2014-05-20 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for a drug delivery device |
| US9345840B2 (en) * | 2009-06-01 | 2016-05-24 | Sanofi-Aventis Deutschland Gmbh | Drug delivery dose setting mechanism with variable maximum dose |
| US9950116B2 (en) * | 2009-06-01 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Dose setting mechanism for priming a drug delivery device |
| US9199040B2 (en) * | 2009-06-01 | 2015-12-01 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device last dose lock-out mechanism |
| US10034982B2 (en) * | 2009-06-01 | 2018-07-31 | Sanofi-Aventis Deutschland Gmbh | Spindle for a drug delivery device |
| US9457150B2 (en) * | 2009-06-01 | 2016-10-04 | Sanofi-Aventis Deutschland Gmbh | Biasing mechanism for a drug delivery device |
| US8974423B2 (en) * | 2009-06-01 | 2015-03-10 | Sanofi-Aventis Deutschland Gmbh | Resettable drug delivery device |
| AU2010287033B2 (en) * | 2009-08-24 | 2012-08-30 | Shl Group Ab | Dose reset mechanism |
| CA2772006A1 (en) * | 2009-09-07 | 2011-03-10 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for drug delivery device |
| EP2292286A1 (en) * | 2009-09-07 | 2011-03-09 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for a medication delivery device and medication delivery device |
| US20120283654A1 (en) * | 2009-09-30 | 2012-11-08 | Sanofi-Aventis Deutschland Gmbh | Button Member for Operating a Drive Assembly |
| AR079004A1 (es) * | 2009-09-30 | 2011-12-21 | Sanofi Aventis Deutschland | Dispositivo de dispensacion de farmacos |
| US9180255B2 (en) * | 2009-09-30 | 2015-11-10 | Sanofi-Aventis Deutschland Gmbh | Resettable drive assembly and drug delivery device |
| US9533107B2 (en) * | 2009-09-30 | 2017-01-03 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device with biasing track for transmitting load to rotatable drive member enabling subsequent dose dispense |
| JP5752692B2 (ja) * | 2009-09-30 | 2015-07-22 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイス用の駆動機構及び駆動機構用のリセット部材の使用 |
| WO2011039209A1 (en) * | 2009-09-30 | 2011-04-07 | Sanofi-Aventis Deutschland Gmbh | Assembly and piston rod for a drug delivery device |
| CA2773459A1 (en) * | 2009-09-30 | 2011-04-07 | Sanofi-Aventis Deutschland Gmbh | Resettable drug delivery device |
| WO2011039210A1 (en) * | 2009-09-30 | 2011-04-07 | Sanofi-Aventis Deutschland Gmbh | Assembly for a drug delivery device |
| BR112012007608A2 (pt) * | 2009-09-30 | 2016-08-23 | Sanofi Aventis Deutschland | mecanismo de acionamento para um dispositivo de distribuição de fármaco e uso de um elemento elástico para um mecanismo de acionamento |
| EP2482901B1 (en) * | 2009-09-30 | 2019-10-23 | Sanofi-Aventis Deutschland GmbH | Injection device |
| AR078459A1 (es) * | 2009-09-30 | 2011-11-09 | Sanofi Aventis Deutschland | Conjunto de accionamiento, vastago de piston, dispositivo para la entrega de drogas, y uso de un resorte |
| EP2482872B2 (en) * | 2009-09-30 | 2019-12-11 | Sanofi-Aventis Deutschland GmbH | Method for assembling a drug delivery device, assembly for a drug delivery device and piston rod for a drug delivery device |
| WO2011039219A2 (en) * | 2009-09-30 | 2011-04-07 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device, assembly for a drug delivery device and method for setting up a drug delivery device |
| US8663174B2 (en) * | 2009-11-13 | 2014-03-04 | Becton, Dickinson And Company | Hub assembly having a hidden needle for a drug delivery pen |
| EP2501421B1 (en) * | 2009-11-20 | 2019-08-21 | Becton Dickinson and Company | Injection device without a gearing |
| BR112012013767A2 (pt) * | 2009-12-07 | 2016-04-26 | Sanofi Aventis Deutschland | montagem de acionamento para um dispositivo de entrega de fármaco e dispositivo de entrega de fármaco |
| JP5973418B2 (ja) * | 2010-03-25 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自動リザーバ係合を備えた薬用モジュール |
| US20110319833A1 (en) * | 2010-06-24 | 2011-12-29 | Thomas Chun | Protective guard for needles of injection devices |
| US8303541B2 (en) * | 2010-06-24 | 2012-11-06 | Thomas Chun | Protective guard for needles of injection devices having removable needle assemblies |
| US8911401B2 (en) * | 2010-07-02 | 2014-12-16 | Sanofi-Aventis Deutschland Gmbh | Safety device for a pre-filled syringe and injection device |
| UA109665C2 (xx) * | 2010-09-24 | 2015-09-25 | Пристрій подачі дози | |
| BR112013008882A2 (pt) * | 2010-10-13 | 2017-07-11 | Sanofi Aventis Deutschland | mecanismo de definição de dose para um dispositivo de administração de fármaco e método de administração de pelo menos uma dose |
| US8128594B1 (en) * | 2010-11-03 | 2012-03-06 | Chang li-feng | Safety syringe |
| EP2489389A1 (en) * | 2011-02-18 | 2012-08-22 | Sanofi-Aventis Deutschland GmbH | Detent mechanism |
| WO2012130704A1 (en) * | 2011-03-25 | 2012-10-04 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device |
| US9220660B2 (en) * | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| US8496619B2 (en) * | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| JP6505108B2 (ja) * | 2013-09-03 | 2019-04-24 | サノフイSanofi | 残っている薬物の量よりも高い用量が設定されることを防止する用量制限ナット付きペン型薬物注射デバイス |
-
2012
- 2012-06-14 WO PCT/EP2012/061249 patent/WO2012171981A1/en not_active Ceased
- 2012-06-14 US US14/126,104 patent/US9731075B2/en not_active Expired - Fee Related
- 2012-06-14 MX MX2013014826A patent/MX357609B/es active IP Right Grant
- 2012-06-14 AR ARP120102110A patent/AR086930A1/es not_active Application Discontinuation
- 2012-06-14 AU AU2012269060A patent/AU2012269060B2/en not_active Ceased
- 2012-06-14 JP JP2014515182A patent/JP6057991B2/ja not_active Expired - Fee Related
- 2012-06-14 CN CN201280039392.1A patent/CN103732278B/zh not_active Expired - Fee Related
- 2012-06-14 CA CA2838786A patent/CA2838786A1/en not_active Abandoned
- 2012-06-14 DK DK12728466.9T patent/DK2720738T3/en active
- 2012-06-14 TW TW101121249A patent/TWI574708B/zh not_active IP Right Cessation
- 2012-06-14 RU RU2014101354/14A patent/RU2603289C2/ru not_active IP Right Cessation
- 2012-06-14 KR KR1020147001290A patent/KR20140050010A/ko not_active Ceased
- 2012-06-14 BR BR112013032089A patent/BR112013032089A2/pt not_active Application Discontinuation
- 2012-06-14 EP EP12728466.9A patent/EP2720738B1/en active Active
-
2013
- 2013-12-08 IL IL229850A patent/IL229850A/en active IP Right Grant
- 2013-12-09 ZA ZA2013/09240A patent/ZA201309240B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201309240B (en) | 2014-08-27 |
| KR20140050010A (ko) | 2014-04-28 |
| CN103732278B (zh) | 2016-02-17 |
| JP2014519917A (ja) | 2014-08-21 |
| CN103732278A (zh) | 2014-04-16 |
| EP2720738B1 (en) | 2016-01-20 |
| RU2603289C2 (ru) | 2016-11-27 |
| MX2013014826A (es) | 2014-03-27 |
| US9731075B2 (en) | 2017-08-15 |
| WO2012171981A1 (en) | 2012-12-20 |
| JP6057991B2 (ja) | 2017-01-11 |
| MX357609B (es) | 2018-07-17 |
| NZ619087A (en) | 2015-04-24 |
| RU2014101354A (ru) | 2015-07-27 |
| AU2012269060B2 (en) | 2016-07-14 |
| AU2012269060A1 (en) | 2014-01-16 |
| CA2838786A1 (en) | 2012-12-20 |
| IL229850A (en) | 2016-10-31 |
| TWI574708B (zh) | 2017-03-21 |
| EP2720738A1 (en) | 2014-04-23 |
| US20140121606A1 (en) | 2014-05-01 |
| BR112013032089A2 (pt) | 2016-12-13 |
| AR086930A1 (es) | 2014-01-29 |
| HK1192175A1 (zh) | 2014-08-15 |
| DK2720738T3 (en) | 2016-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI574708B (zh) | 用於藥物遞送裝置的卡匣支撐器總成 | |
| US9242046B2 (en) | Coded cartridge assembly | |
| CN102917739B (zh) | 具有可弯曲的锁定元件的编码药物贮存器连接元件 | |
| CN102740909B (zh) | 药筒保持器、给药装置和用于将药筒固定在药筒保持器中的方法 | |
| JP5943834B2 (ja) | 薬物送達デバイスのための取り付け方法及び連結アセンブリ | |
| AU2011287530B2 (en) | Method and system for retaining a cartridge in a holder | |
| RU2552887C2 (ru) | Поршень для картриджа и поршневой шток для устройства доставки лекарственных средств | |
| CN103153368B (zh) | 用于防止选择剂量的机构 | |
| CN102946929A (zh) | 具有共用紧固机构的筒组件和药物输送装置 | |
| CN103153367A (zh) | 用于药物输送装置贮液器的连接器 | |
| JP2014501120A (ja) | 薬物送達デバイス用のニードル・アセンブリ | |
| JP2013542799A (ja) | 用量設定機構及び薬物送達デバイス | |
| JP2013524906A (ja) | 薬物送達デバイス用のコード化フェルール | |
| JP2014502891A (ja) | 専用カートリッジ及びホルダ | |
| US9649447B2 (en) | Flexible fastener for drug delivery device | |
| HK1192175B (zh) | 用於给药装置的药筒保持器组件 | |
| NZ619087B2 (en) | Cartridge holder assembly for drug delivery devices |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |